Mitchell H. Gold, MD, has gone from heading Dendreon, whose pioneering prostate cancer immunotherapy failed to meet initial sales expectations, to success as Founder and Managing Partner of life sciences investment firm Alpine BioVentures, and Executive Chairman and CEO of Alpine Immune Sciences . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge